Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban outcomes and pharmacokinetics in adults with short bowel syndrome on long-term parenteral nutrition
NL-OMON28143Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivaroxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE), sponsored by Amsterdam University Medical Center. Primary endpoints: Venous thromboembolism after one year, Cerebrovascular stroke after one year and 2 more. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON28143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28143.